SAN DIEGO–(BUSINESS WIRE)–Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology, today announced the publication of data in the Journal of Cardiovascular Electrophysiology (JACE) demonstrating vMap’s ability to reduce the time from mapping to treatment, procedure duration, and fluoroscopy when treating cardiac arrhythmia patients with ablation therapy.
“A 22.6% reduction in procedure duration is significant”
The study, “Impact Of Artificial Intelligence Arrhythmia Mapping on Time to First Ablation, Procedure Duration, and Fluoroscopy Use,” is a retrospective, case-controlled study of 28 patients with common arrhythmia types. Designed to evaluate the impact of AI ECG mapping on time to ablation, procedural duration, and fluoroscopy, key data points from the study demonstrate vMap’s ability to deliver:
- 19.0% reduction in time to ablation (133 ± 48 vs. 165 ± 49 min, p = 0.02)
- 22.6% reduction in procedure duration (233 ± 51 vs. 301 ± 83 min, p < 0.001)
- 43.7% reduction in fluoroscopy (18.7 ± 13.3 vs. 33.2 ± 18.0 min, p < 0.001)
Additionally, at six-month follow-up, arrhythmia-free survival was evident in 73.5% of the study group compared to 63.3% of the control group (p = 0.56).
“A 22.6% reduction in procedure duration is significant,” said Dr. Sutton Fox, University of California, San Diego. “By employing AI ECG arrhythmia mapping using 12-lead ECG data, the study shows increased procedural efficiency and improved patient safety by limiting exposure to fluoroscopy. These meaningful advantages can drastically improve lab throughput and increase patient access to treatment.”
“As the patient population suffering from cardiac arrhythmias continues to increase, reducing treatment procedure times without compromising outcomes is critical,” said Rob Krummen, CEO of Vektor Medical. “The compelling data published in JACE further validates vMap’s ability to do precisely that. EPs can rely on vMap to reduce procedure times with increased confidence in positive outcomes. This evidence of impact is driving the adoption of vMap throughout the United States in leading health systems.”
The JACE publication is the third peer-reviewed study since late 2021 demonstrating vMap’s potential to help physicians rapidly and accurately identify arrhythmia source locations. A September 2022 article published in Circulation: Arrhythmia and Electrophysiology demonstrated that vMap’s computational ECG mapping using a forward-solution approach exceeded prespecified accuracy goals for arrhythmia and pacing localization. An October 2021 article published in Heart Rhythm O2 showed that a workflow that includes computational ECG mapping and protocol-guided respiratory gating is feasible and safe and may improve stereotactic ablative radiotherapy planning.
About vMap®
vMap is the only FDA-cleared, non-invasive AI-based solution for mapping arrhythmias, utilizing just a 12-lead ECG. vMap localizes arrhythmia sources for focal and fibrillation-type arrhythmias, including atrial fibrillation. By unlocking actionable insights contained within a standard 12-lead ECG, vMap enables physicians to rapidly and accurately locate arrhythmia source locations. Backed by extensive clinical evidence, vMap not only improves patient outcomes but also reduces procedure time, optimizing workflow across the entire arrhythmia care pathway.
About Vektor Medical
Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-based, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. For more information about vMap and Vektor Medical, please visit www.vektormedical.com
Contacts
Media Contact
Stacey Holifield
(617) 233-3873
vektor@levitatenow.com
